The primary objective of this study is to compare the effect of Welchol in combination with TriCor compared to TriCor alone on low-density lipoprotein cholesterol (LDL-C) in patients with high cholesterol.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
129
Colesevelam 625 mg tablets - 6 tablets/day Fenofibrate 160 mg tablet - 1/day
fenofibrate tablets 160 mg - 1/day + Welchol placebo tablets - 6/day
fenofibrate 160 mg tablet - 1/day and Welchol placebo tablets - 6/day
Unnamed facility
Longwood, Florida, United States
Unnamed facility
Ocala, Florida, United States
Unnamed facility
Winterpark, Florida, United States
Unnamed facility
Chicago, Illinois, United States
% change in LDL-C from baseline
Time frame: 6 weeks
The absolute change in LDL-C from baseline
Time frame: 6 weeks
The absolute change and % change in LDL-C from week -8 (untreated)
Time frame: 14 weeks
The percentage of patients who achieved target LDL-C
Time frame: 6 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Lombard, Illinois, United States
Unnamed facility
Overland Park, Kansas, United States
Unnamed facility
Stateville, North Carolina, United States
Unnamed facility
Cincinnati, Ohio, United States
Unnamed facility
San Antonio, Texas, United States
Unnamed facility
Richmond, Virginia, United States